

Message

From: Kaiser, Sven-Erik [Kaiser.Sven-Erik@epa.gov]
Sent: 4/7/2020 9:54:15 PM
To: Keigwin, Richard [Keigwin.Richard@epa.gov]
CC: Weiss, Steven [Weiss.Steven@epa.gov]; Pease, Anita [Pease.Anita@epa.gov]; Willis, Kristen [Willis.Kristen@epa.gov]
Subject: Re: Rep. Carbajal Inquiry on Shield Sanitizer

Sending

On Apr 7, 2020, at 5:53 PM, Keigwin, Richard <Keigwin.Richard@epa.gov> wrote:

Yes

From: Kaiser, Sven-Erik <Kaiser.Sven-Erik@epa.gov>
Sent: Tuesday, April 07, 2020 5:48 PM
To: Weiss, Steven <Weiss.Steven@epa.gov>; Pease, Anita <Pease.Anita@epa.gov>; Willis, Kristen <Willis.Kristen@epa.gov>; Keigwin, Richard <Keigwin.Richard@epa.gov>
Subject: RE: Rep. Carbajal Inquiry on Shield Sanitizer

Ok to send or need OCSPP IO review?

Sven-Erik Kaiser
U.S. EPA
Office of Congressional and Intergovernmental Relations
1200 Pennsylvania Ave., NW (1305A)
Washington, DC 20460
202-566-2753 (o)
202-591-0619 (c)

From: Weiss, Steven
Sent: Tuesday, April 07, 2020 5:41 PM
To: Kaiser, Sven-Erik <Kaiser.Sven-Erik@epa.gov>
Cc: Pease, Anita <Pease.Anita@epa.gov>; Willis, Kristen <Willis.Kristen@epa.gov>
Subject: RE: Rep. Carbajal Inquiry on Shield Sanitizer

Sven-
pls see the below from Kristen.
Thanks
-Steve

Based on the information provided it does not appear that they would need to submit an efficacy protocol as the product is described as a liquid which is effective in 10 minutes. Our [OCSPP 810 efficacy guidelines](#), in particular chapter 810.2200 for disinfectants provides the standard methodology needed for efficacy testing for disinfectants. None of our standard methods require validation via electron microscopy. In addition, it would not be necessary to test specifically against SARS-CoV-2 in order to be listed as a product on [EPA's list N: Products for use against SARS-CoV-2](#). Testing to support the base disinfection claim and a non-SARS-CoV-2 coronavirus or any non-enveloped virus would be sufficient for inclusion on List N. Note it is not necessary to work with SARS-CoV-2 under biosafety level 4 (BSL-4) conditions. BSL-3 is sufficient: <https://www.beiresources.org/Collection/56/SARS-CoV-2.aspx>

We don't typically provide names of testing labs since we don't want it to be viewed as an endorsement. Typically we provide a link to the GLP inspection list which includes labs for which inspections were completed and note that not all labs conduct efficacy testing: <https://www.epa.gov/compliance/epa-good-laboratory-practices-inspections-0>

From: Kaiser, Sven-Erik <Kaiser.Sven-Erik@epa.gov>
Sent: Tuesday, April 7, 2020 3:02 PM
To: Grable, Melissa <Grable.Melissa@epa.gov>; Hanley, Mary <Hanley.Mary@epa.gov>; Tyler, Tom <Tyler.Tom@epa.gov>; Keigwin, Richard <Keigwin.Richard@epa.gov>; Messina, Edward <Messina.Edward@epa.gov>; Dinkins, Darlene <Dinkins.Darlene@epa.gov>; Pease, Anita <Pease.Anita@epa.gov>; Weiss, Steven <Weiss.Steven@epa.gov>; Kolb, John (JohnMark) <kolb.john@epa.gov>; Levine, Carolyn <Levine.Carolyn@epa.gov>; Gill, Sonam <Gill.Sonam@epa.gov>
Subject: Rep. Carbajal Inquiry on Shield Sanitizer

Coronavirus Team – please see the inquiry from Rep. Carbajal on the Hospital Enviro Shield product that came through our colleague Sonam Gill in R9. This looks like a new product that needs testing assistance. Sonam provided the basic mailbox info (including the CDX ask). Please let us know our response and if any questions. Best,
Sven

Sven-Erik Kaiser
U.S. EPA
Office of Congressional and Intergovernmental Relations
1200 Pennsylvania Ave., NW (1305A)
Washington, DC 20460
202-566-2753 (o)
202-591-0619 (c)

From: Haas, Greg <Greg.Haas@mail.house.gov>
Sent: Tuesday, April 7, 2020 10:41 AM
To: Gill, Sonam <Gill.Sonam@epa.gov>
Subject: FW: Shield Sanitizer

Here is the information about the product we spoke about on the phone.

Greg Haas

Greg Haas
Senior District Representative
Congressman Salud Carbajal (CA-24)
1411 Marsh St., Ste 205
San Luis Obispo, CA 93401
(805) 546-8348w
(805) 699-1442c
(805) 439-3574fx
Greg.Haas@mail.house.gov

<https://carbajal.house.gov/>

New COVID-19 Protocols: Per guidance from the Centers for Disease Control, community members are encouraged to take precautions, including cleaning your hands often, practicing social distancing, and staying home as much as possible to further reduce risk of being exposed to COVID-19. Please avoid handshakes and limit close contact with staff. If you need to reschedule your appointment, or prefer to speak with our team over the phone, please let us know and we will accommodate.

From: Ahmad Nooristani; **Ex. 6 PP – personal email**
Sent: Thursday, March 26, 2020 8:39 PM
To: Haas, Greg <Greg.Haas@mail.house.gov>
Subject: Shield Sanitizer

Good Evening Greg;

It was nice talking to you and thank you for helping us to get this product to the nation and save some lives. The product has exceptional capacity that could transform how we deal with current and future situation. On our behave please thank Congressman for his eagerness to help. He has been a great supporter for the many years. Please let me know if you have any questions or require more documents.

My cell phone **Ex. 6 PP – personal phone** and above email can serve as direct line of communication with me.

Thank you

Why are we writing you? What help do we need?

- <!--[if !supportLists]--><!--[endif]-->**What we need is quick access to Level 4 testing laboratory to demonstrate this efficacy of this product on the actual COVID-19 virus.** This lab must have atomic microscopy scanning capability as well as electron scanning microscopy. With this equipment, the actual kill dynamics will be visible to the eye and mechanism at molecular level clearly visible. Our goal is to demonstrate beyond doubt that it is effective with the COVID-19 virus. (This kill dynamic is non-discretionary. It is not a chemical or biological based (poison based) kill dynamic. The proven observable encapsulation and kill process works on any and all microbes present on the target surface.) Proving this opens the door to the possibility of radical control of the microbial environment of hospitals and treatment centers. And protecting the lives of our health professionals.
- <!--[if !supportLists]--><!--[endif]-->**We also need communication (and coordination) with EPA, possibly FDA, and/or CDC in order to create a clear pathway for this product to reach front lines of application without roadblocks.** With the approval of these organizations, a quick spread of informed application of product where needed would result without unnecessary hindrance

Attached are the documents you requested.

I included the complete Toxicity reports in addition to the 4 docs.

1. Product Description Letter (Hospital Enviro Shield)
2. Toxicity Overview (Non-Toxicity Overview)
3. Science Research Report (05 Science Paper)
4. Ingredients
5. Toxicity 6 (actual study results)